Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies

Overview

Journal Diabetes Spectr

Specialty Endocrinology

Date 2024 Feb 22

PMID 38385098

Authors

Idoia Genua

Kenneth Cusi

Affiliations

Soon will be listed here.

Abstract

Nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic steatohepatitis (NASH), can promote the development of cirrhosis, hepatocellular carcinoma, cardiovascular disease, and type 2 diabetes. Similarly, type 2 diabetes confers the greatest risk for the development of NASH, especially when associated with obesity. Although lifestyle changes are critical to success, early implementation of pharmacological treatments for obesity and type 2 diabetes are essential to treat NASH and avoid disease progression. This article reviews current guidance regarding the use of pharmacological agents such as pioglitazone, glucagon-like peptide 1 receptor agonists, and sodium-glucose cotransporter 2 inhibitors in the setting of NAFLD and NASH. It also reviews the latest information on new drugs currently being investigated for the treatment of NASH.

Citing Articles

Clinical Assessment of Common Medications for Nonalcoholic Fatty Liver Disease: A Systematic Review and Bayesian Network Meta-Analysis.

Shi R, Chai K, Wang H, Zhou J, Yang S, Li J J Evid Based Med. 2025; 18(1):e70002.

PMID: 39963857 PMC: 11833758. DOI: 10.1111/jebm.70002.

The Many Facets of PPAR-γ Agonism in Obesity and Associated Comorbidities: Benefits, Risks, Challenges, and Future Directions.

Kounatidis D, Vallianou N, Rebelos E, Kouveletsou M, Kontrafouri P, Eleftheriadou I Curr Obes Rep. 2025; 14(1):19.

PMID: 39934485 DOI: 10.1007/s13679-025-00612-4.

Nonlinear relationship between hepatic steatosis index and reversion to normal glucose regulation in Chinese adults with prediabetes.

Zeng H, Yu F, Hu H, Han Y, Ye R, Cao C Sci Rep. 2025; 15(1):4269.

PMID: 39905126 PMC: 11794635. DOI: 10.1038/s41598-025-88314-8.

The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment.

Michalopoulou E, Thymis J, Lampsas S, Pavlidis G, Katogiannis K, Vlachomitros D J Clin Med. 2025; 14(2).

PMID: 39860434 PMC: 11765821. DOI: 10.3390/jcm14020428.

Diverting hepatic lipid fluxes with lifestyles revision and pharmacological interventions as a strategy to tackle steatotic liver disease (SLD) and hepatocellular carcinoma (HCC).

Misceo D, Mocciaro G, DAmore S, Vacca M Nutr Metab (Lond). 2024; 21(1):112.

PMID: 39716321 PMC: 11668039. DOI: 10.1186/s12986-024-00871-3.

References

Hampp C, Pippins J . Pioglitazone and bladder cancer: FDA's assessment. Pharmacoepidemiol Drug Saf. 2017; 26(2):117-118. DOI: 10.1002/pds.4154. View

Davies M, Aroda V, Collins B, Gabbay R, Green J, Maruthur N . Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022; 45(11):2753-2786. PMC: 10008140. DOI: 10.2337/dci22-0034. View

Julian M, Pera G, Soldevila B, Caballeria L, Julve J, Puig-Jove C . Atherogenic dyslipidemia, but not hyperglycemia, is an independent factor associated with liver fibrosis in subjects with type 2 diabetes and NAFLD: a population-based study. Eur J Endocrinol. 2021; 184(4):587-596. DOI: 10.1530/EJE-20-1240. View

Bril F, Biernacki D, Kalavalapalli S, Lomonaco R, Subbarayan S, Lai J . Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care. 2019; 42(8):1481-1488. DOI: 10.2337/dc19-0167. View

Lazarus J, Mark H, Anstee Q, Arab J, Batterham R, Castera L . Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol. 2021; 19(1):60-78. DOI: 10.1038/s41575-021-00523-4. View

Musso G, Cassader M, Paschetta E, Gambino R . Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis. JAMA Intern Med. 2017; 177(5):633-640. PMC: 5470366. DOI: 10.1001/jamainternmed.2016.9607. View

Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L . Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology. 2008; 135(1):100-10. DOI: 10.1053/j.gastro.2008.03.078. View

Bajaj H, Burrows M, Blavignac J, Paron E, Camacho F, Gould E . Extended-release naltrexone/bupropion and liver health: Pooled, post hoc analysis from four randomized controlled trials. Diabetes Obes Metab. 2020; 23(3):861-865. DOI: 10.1111/dom.14284. View

Lebovitz H . Thiazolidinediones: the Forgotten Diabetes Medications. Curr Diab Rep. 2019; 19(12):151. PMC: 6881429. DOI: 10.1007/s11892-019-1270-y. View

10.

Flint A, Andersen G, Hockings P, Johansson L, Morsing A, Sundby Palle M . Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2021; 54(9):1150-1161. PMC: 9292692. DOI: 10.1111/apt.16608. View

11.

Zhou Y, Huang Y, Ji X, Wang X, Shen L, Wang Y . Pioglitazone for the Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with or at High Risk of Type 2 Diabetes Mellitus: A Meta-Analysis. J Clin Endocrinol Metab. 2019; 105(5). DOI: 10.1210/clinem/dgz252. View

12.

Lingvay I, Cheng A, Levine J, Gomez-Valderas E, Allen S, Ranta K . Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the.... Diabetes Obes Metab. 2022; 25(4):965-974. DOI: 10.1111/dom.14943. View

13.

Younossi Z, Golabi P, Paik J, Henry A, Van Dongen C, Henry L . The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023; 77(4):1335-1347. PMC: 10026948. DOI: 10.1097/HEP.0000000000000004. View

14.

Vanderheiden A, Harrison L, Warshauer J, Adams-Huet B, Li X, Yuan Q . Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin. J Clin Endocrinol Metab. 2016; 101(4):1798-806. DOI: 10.1210/jc.2015-3906. View

15.

DeFronzo R, Inzucchi S, Abdul-Ghani M, Nissen S . Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes. Diab Vasc Dis Res. 2019; 16(2):133-143. DOI: 10.1177/1479164118825376. View

16.

Kanwal F, Shubrook J, Younossi Z, Natarajan Y, Bugianesi E, Rinella M . Preparing for the NASH Epidemic: A Call to Action. Diabetes Care. 2021; 44(9):2162-2172. DOI: 10.2337/dci21-0020. View

17.

Gastaldelli A, Cusi K, Lando L, Bray R, Brouwers B, Rodriguez A . Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022; 10(6):393-406. DOI: 10.1016/S2213-8587(22)00070-5. View

18.

Takahashi H, Kessoku T, Kawanaka M, Nonaka M, Hyogo H, Fujii H . Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD. Hepatol Commun. 2021; 6(1):120-132. PMC: 8710792. DOI: 10.1002/hep4.1696. View

19.

Harrison S, Gawrieh S, Roberts K, Lisanti C, Schwope R, Cebe K . Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. J Hepatol. 2021; 75(2):284-291. DOI: 10.1016/j.jhep.2021.02.034. View

20.

Bolinder J, Ljunggren O, Kullberg J, Johansson L, Wilding J, Langkilde A . Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012; 97(3):1020-31. DOI: 10.1210/jc.2011-2260. View